Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A review of methionine dependency in modern cancer therapy

6

Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

Building global standards for antimicrobial policy

6

Mar 2026

Building global standards for antimicrobial policy

Antimicrobial resistance (AMR) threatens human, animal, and environmental health globally. An international team from leading institutions, including the University of Edinburgh, London School of Hygiene and Tropical Medicine, North Carolina State University, and the International Centre for Antimicrobial Resistance Solutions, identifies fundamental gaps in current mathematical modelling approaches that prevent translation of science into policy, including data limitations, knowledge gaps about AMU-AMR relationships, and the absence of international coordination mechanisms similar to climate change efforts. They call for transdisciplinary collaboration to build integrated modelling architectures.

Melbourne’s lab-grown "skin" revolutionizes tick research

5

Mar 2026

Melbourne’s lab-grown "skin" revolutionizes tick research

The world's first lab-based tick feeding system for bush ticks, developed by researchers at the University of Melbourne, has transformed the study of ticks and how they transmit disease. The novel, host-free technology reduces the need for animal experiments in tick studies, facilitating more ethical, reproducible research.

Dual targeting strategy may improve treatment for resistant lung cancers

5

Mar 2026

Dual targeting strategy may improve treatment for resistant lung cancers

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Mercury Pharmaceuticals
Mercury Pharmaceuticals

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.